Clinical Trial Update: Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sulforaphane to reduce risk of psychosis in individuals at clinical high risk.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clinical High Risk Syndrome of Psychosis

Drugs mentioned

• Sulforaphane (sulforaphane)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: Clinical High Risk Syndrome of Psychosis | Phase 3 | Status: ACTIVE_NOT_RECRUITING